Valvular & structural heart diseaseRandomised controlled trial
Timing of Percutaneous Coronary Intervention (PCI) in Patients Undergoing Transcatheter Aortic-Valve Implantation
- Randomised controlled trial
- international
- open-label
- non-inferiority
- 48 centres in Europe
Authors' conclusion
Among patients with severe aortic stenosis and coronary artery disease, a strategy of TAVI before PCI was noninferior to a strategy of PCI before TAVI with respect to the primary end point at 1 year.
Study context
- Population
- Patients with severe AS and CAD
- Participants
- 986 patients
- Comparison
- Transcatheter aortic-valve implantation (TAVI) before PCI vs PCI before TAVI
- TAVI-firstn = 498
- PCI-firstn = 488reference
- Primary endpoint
- Composite of:
- All-cause death
- Nonfatal MI
- Ischemia-driven revascularization
- Rehospitalization related to the valve
- Procedure or HF
- Life-threatening
- Disabling
- Major bleeding
- Follow-up
- 1 year after randomization
Primary result
As reported in the abstract
1 year
Risk difference
−2.0 percentage points
95% CI −7.4 to 3.4
P < 0.001 for non-inferiority
Events by treatment group
TAVI-first vs PCI-first
risk difference −2.0 percentage points (95% CI −7.4 to 3.4); P for non-inferiority < 0.001
Safety
events
| Outcome | TAVI-first | PCI-first |
|---|---|---|
| Serious adverse events | 264 | 273 |
Original publication
Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation. N Engl J Med. Published 30 August 2026. doi:10.1056/nejmoa2606924
Summarised from the published abstract; every number is checked against it